Plain Language Summary
Narrative review examining pharmacological strategies to preserve lean body mass during weight loss—including GLP-1/GIP receptor agonist-induced weight loss—covering tesamorelin alongside anabolic agents such as testosterone, SARMs, and myostatin inhibitors. Discusses the lean mass preservation challenge specifically in the context of incretin-based obesity therapies. Positions tesamorelin within the emerging landscape of body composition optimization—establishing its evidence base as a GH-axis modulator that selectively reduces visceral fat without inducing the lean mass loss that complicates GLP-1 RA weight reduction programs, relevant for preserving functional muscle in obese patients treated with semaglutide or tirzepatide.
Abstract
: Overweight and obesity are becoming increasingly prevalent. Incretin-based obesity treatments-glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucagon-like peptide-1 receptor/glucose-dependent insulinotropic polypeptide receptor agonists (GIP/GLP-1 RAs or dual agonists)-are a major stride in the evolution of obesity management. However, like weight loss with other means, they are associated with an inadvertent significant loss of lean body mass, including muscle. This has led to a resurgence in research for the preservation of lean body mass, the loss of which occurs with weight loss. The purpose of this narrative review is to discuss the mechanisms involved with lean body loss and capture the research landscape of the different classes of pharmacological agents being developed to address this problem.: We queried PubMed, Medline, and Scopus for randomized controlled trials and phase II or phase III trials using key words to capture the breath of this topic-obesity, weight loss, muscle loss, lean mass, and muscle preservation. Animal studies were excluded. We analyzed the studies conducted to date.: Weight loss, regardless of the method used to achieve it, is inadvertently accompanied by lean body mass loss, to varying degrees. There are several mechanisms that govern the loss of lean body mass and, more specifically, the loss of muscle mass; as such, several classes of medications have been explored, targeting different pathways and receptors-including bimagrumab (activin receptor agonist), tesamorelin (growth hormone releasing hormone agonists), and enobosarm (selective androgen receptor modulator). Most of these drugs are in the early phases of research development, but some show great promise.: This narrative review attempts to detail the physiology of muscle mass loss when accompanied by weight loss and identify pharmacological targets that can be utilized to minimize it with mechanisms, effects, side effects, and research developmental progress.
Authors
Arora, Gunjan; Conde, Katherine R; Desouza, Cyrus V